These findings indicate the presence of a novel drug resistance pathway independent of CRBN induction and suggest that NCoR2 expression may be a potential biomarker for study of immunomodulatory imide drug refractory disease and could be applied to regulate MYC expression to overcome MDR in cancer cells. Here, NCOR2 is linked to cancer.